CG Oncology Is Maintained at Outperform by RBC Capital

RBC Raises Price Target on CG Oncology to $73 From $61, Keeps Outperform, Speculative Risk

CG Oncology price target raised to $73 from $61 at RBC Capital

CG Oncology Is Maintained at Overweight by Piper Sandler

CG Oncology price target raised to $70 from $55 at Piper Sandler

CG Oncology Expands At-The-Market Equity Offering Capacity

CG Oncology Inc Files for Offering of up to $550 Mln Common Stock - SEC Filing

CG Oncology Director James Mulay Reports Disposal of Common Shares

CG Oncology Is Maintained at Buy by Truist Securities

Wedbush Raises Price Target on CG Oncology to $77 From $70, Keeps Outperform Rating

Accelerated Creto Trajectory in NMIBC Drives Earlier Data, De-Risked Commercialization, and Higher $66 Target Supporting Buy Rating on CG Oncology

CG Oncology price target raised to $66 from $62 at Truist

CG Oncology price target raised to $93 from $89 at Morgan Stanley

CG Oncology Up Over 27%, on Track for Record High Close and Record Percent Increase -- Data Talk

Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January

CG Oncology: Early PIVOT-006 Readout, Strengthened Creto Outlook, and 2026 Catalyst Wave Support Buy Rating and Higher $85 Target

CG Oncology rises 16.0%

CG Oncology Accelerates Phase 3 Bladder Cancer Trial Timeline